Prior authorization requirements for Part B injectable/infusible drugs:
Aliqopa (copanlisib injection), Cinvanti (aprepitant injection) and Opsiria (sirolimus injection)

Background: On March 1, 2018, Amerigroup prior authorization (PA) requirements will change for three Part B injectable/infusible drugs: Aliqopa (copanlisib injection), Cinvanti (aprepitant injection) and Opsiria (sirolimus injection). Federal and state law as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

PA requirements will be added to the following codes, which are Part B drugs billed with not otherwise classified (NOC) HCPCS J codes J3490, J3590 and J9999, unlisted because no J code has been established at this time:
- Aliqopa (copanlisib injection): for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments (J9999)
- Cinvanti (aprepitant injection): for the treatment of chemotherapy-induced nausea and vomiting (J3490, J3590)
- Opsiria (sirolimus injection): for the treatment of uveitis, which works by blocking an enzyme called mammalian target of rapamycin (J3490, J3590)

Since these codes include all drugs that are NOC, if the authorization is denied for medical necessity, the plan’s denial will be for the drug and not the HCPCS code.

Not all PA requirements are listed here. Detailed PA requirements are available to contracted providers by accessing the Provider Self-Service Tool within Availity. Noncontracted providers should contact the health plan.

What if I need assistance?
If you have questions about this communication, received this fax in error or need assistance with any other item, contact your local Provider Relations representative or call 1-866-805-4589.